BCL2L11 and chronic myelogenous leukemia, BCR-ABL1 positive: This study shows that it is feasible to switch BIM splicing so as to enhance production of proapoptotic BIM isoforms, and thereby resensitize resistant BIM deletion-containing CML cell lines to imatinib.